Researchers from Josep Carreras Leukemia Research Institute participate in an international study that confirms for the first time that mutation of the two TP53 gene’s copies is associated with a worse prognosis in myelodysplastic syndromes, a group of blood cancers a more frequent in elderly population. The results of this study have been published in Nature Medicine journal and represent an advance in the diagnosis and treatment of this type of hematological cancer.
- Advancing gene editing with new CRISPR/Cas9 variant
- New review confirms disproportionate impact of COVID-19 on Black, Hispanic populations
- Low-dose CT for lung cancer screening: benefit outweighs potential harm
- Chemists get peek at novel fluorescence
- Tech makes it possible to digitally communicate through human touch